PR Newswire Clinical TrialsOriginal article
Accro Bioscience to Present Phase Ib Data of AC-101, an Oral Selective RIPK2 Inhibitor, for Moderate-to-Severe UC at UEG Week 2026 in Barcelona
Phase 1AC-101Positive
AI Analysis
Summary
Accro Bioscience announced it will present Phase 1b efficacy and safety data for AC-101, an oral selective RIPK2 inhibitor, for moderate-to-severe ulcerative colitis at UEG Week 2026 in Barcelona.
Clinical Trial Data
Phase
1b
Outcome Details
Phase 1b efficacy and safety data to be presented
Importance:5/10
Sentiment:
0.30
Phase 1boral selective RIPK2 inhibitorulcerative colitisimmune mediated diseasesconference presentation
Read the original article
Published by PR Newswire Clinical Trials on August 13, 2026 11:00 AM